Reviva Pharmaceuticals Holdings, Inc. (RVPH) Income Statement
RVPH 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRVPH revenue and net income
RVPH growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RVPH quarterly EPS vs estimates
Reviva Pharmaceuticals beat the analyst EPS estimate in 4 of the last 8 quarters.
RVPH income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | — | — | — | — | $724,740 | — | — |
| Gross profit | — | — | — | — | — | −$724,740 | — | — |
| Research & development | $11.7M | $22.9M | $31.4M | $18.9M | $4.9M | $295,150 | $195,744 | $946,301 |
| Sales, general & admin | $8.5M | $7.9M | $8.1M | $5.4M | $5.3M | $2.1M | $181,116 | $175,579 |
| Total operating expenses | $20.2M | $30.8M | $39.5M | $24.3M | $10.1M | $2.4M | $376,860 | $1.1M |
| Operating income | −$20.2M | −$30.8M | −$39.5M | −$24.3M | −$10.1M | −$2.4M | −$376,860 | −$1.1M |
| Interest income | $311,370 | $361,369 | $498,964 | $182,802 | — | $105,183 | $201 | — |
| Interest expense | $13,402 | $18,497 | $33,725 | $182,802 | $2,414 | $1.5M | $469,373 | $557,675 |
| Income before taxes | −$19.8M | −$29.9M | −$39.2M | −$24.3M | −$8.5M | −$3.8M | −$846,032 | −$1.7M |
| Income taxes | $18,889 | $19,514 | $16,949 | $20,777 | $6,004 | $800 | $800 | $800 |
| Net income | −$19.9M | −$29.9M | −$39.3M | −$24.3M | −$8.5M | −$3.8M | −$846,832 | −$1.7M |
| EBITDA | −$19.8M | $918,094 | $259,744 | $3.9M | −$8.5M | −$2.4M | −$376,215 | −$1.1M |
| EPS (diluted) | −$11.39 | −$16.10 | −$26.15 | −$17.78 | −$5.12 | −$3.45 | $2.89 | $2.77 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research & development | $1.39T | $1.4M | $1.7M | $2.1M | $3.7M | $4.1M | $4.7M | $6.9M | $5.6M | $5.8M | $8.5M | $8.7M |
| Sales, general & admin | $1.22T | $1.8M | $1.8M | $1.9M | $2.3M | $2.4M | $1.6M | $1.6M | $2.5M | $2.1M | $1.5M | $2.0M |
| Total operating expenses | $2.62T | $3.3M | $3.6M | $4.0M | $6.1M | $6.5M | $6.3M | $8.5M | $8.1M | $7.9M | $10.0M | $10.7M |
| Operating income | −$2.62T | −$3.3M | −$3.6M | −$4.0M | −$6.1M | −$6.5M | −$6.3M | −$8.5M | −$8.1M | −$7.9M | −$10.0M | −$10.7M |
| Interest income | $176,319 | $89,354 | $143,309 | $59,103 | $22,847 | $86,111 | $47,413 | $53,248 | $87,610 | $173,098 | $157,110 | $91,763 |
| Interest expense | $2.94B | $6,653 | $5,620 | $2,605 | $4,797 | $11,620 | $4,711 | $5,146 | $5,153 | $3,487 | — | $5,901 |
| Income before taxes | −$2.45T | −$3.2M | −$3.4M | −$4.0M | −$6.0M | −$6.4M | −$6.3M | −$8.4M | −$7.9M | −$7.4M | −$9.7M | −$10.5M |
| Income taxes | $2.63B | $3,346 | $2,882 | $2,840 | $7,954 | $5,213 | — | — | $7,385 | $7,396 | — | $12,117 |
| Net income | −$2.45T | −$3.2M | −$3.4M | −$4.0M | −$6.1M | −$6.4M | −$6.3M | −$8.4M | −$7.9M | −$7.4M | −$9.7M | −$10.5M |
| EBITDA | −$2.62T | −$3.2M | −$3.4M | −$4.0M | −$6.0M | −$6.4M | — | $101,882 | $282,263 | $499,381 | — | $854,907 |
| EPS (diluted) | −$0.19 | −$0.46 | −$5.19 | −$1.20 | −$2.40 | −$2.60 | −$0.90 | −$5.00 | −$5.20 | −$5.00 | −$0.35 | −$8.80 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RVPH's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RVPH financial results
Reviva Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $19.9 million. Diluted earnings per share came to −$11.39.
See the RVPH stock overview for the latest quote and news, or the RVPH chart for price history and technical indicators.
RVPH income statement FAQ
Does Reviva Pharmaceuticals have revenue?
Reviva Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Reviva Pharmaceuticals profitable?
No. Reviva Pharmaceuticals reported a net loss of $19.9 million in fiscal 2025.
How much does Reviva Pharmaceuticals spend on research and development?
Reviva Pharmaceuticals spent $11.7 million on research and development in fiscal 2025.
What are Reviva Pharmaceuticals's earnings per share?
Reviva Pharmaceuticals earned $-11.39 per diluted share in fiscal 2025, compared with $-16.10 a year earlier.
When does Reviva Pharmaceuticals's fiscal year end?
Reviva Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.